Franklin Street Advisors Inc Supernus Pharmaceuticals, Inc. Transaction History

Franklin Street Advisors Inc

$1.5 Billion
Q4 2024

A detailed history of Franklin Street Advisors Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Franklin Street Advisors Inc holds 20,000 shares of SUPN stock, worth $749,800. This represents 0.05% of its overall portfolio holdings.

Number of Shares

20,000

Previous 20,000 -0.0%

Holding current value

$749,800

Previous $624,000 15.87%

% of portfolio

0.05%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$25.77 - $35.16 $3,607 - $4,922	-140 Reduced 0.7%	20,000 $624,000
Q2 2023 Jul 13, 2023	BUY	$29.91 - $38.73 $4,187 - $5,422	140 Added 0.7%	20,140 $605,000
Q1 2022 Apr 18, 2022	SELL	$28.51 - $32.9 $32,643 - $37,670	-1,145 Reduced 5.41%	20,000 $646,000
Q4 2021 Jan 26, 2022	SELL	$26.37 - $34.22 $501,030 - $650,180	-19,000 Reduced 47.33%	21,145 $617,000
Q3 2021 Oct 22, 2021	BUY	$23.54 - $31.39 $423,720 - $565,020	18,000 Added 81.28%	40,145 $1.07 Million
Q2 2021 Aug 05, 2021	SELL	$26.72 - $33.19 $53,440 - $66,380	-2,000 Reduced 8.28%	22,145 $682,000
Q3 2020 Oct 21, 2020	SELL	$20.2 - $25.05 $90,900 - $112,725	-4,500 Reduced 15.71%	24,145 $503,000
Q1 2019 May 14, 2019	SELL	$32.77 - $41.99 $1,802 - $2,309	-55 Reduced 0.19%	28,645 $1 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $15,420 - $24,755	-500 Reduced 1.71%	28,700 $953,000
Q4 2017 Jan 10, 2018	SELL	$36.4 - $42.6 $7,280 - $8,520	-200 Reduced 0.68%	29,200 $1.16 Million
Q3 2017 Oct 11, 2017	BUY	$36.75 - $49.65 $1.08 Million - $1.46 Million	29,400	29,400 $1.18 Million

Others Institutions Holding SUPN

# of Institutions

279

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.01B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Franklin Street Advisors Inc with notifications on news.

Account

Franklin Street Advisors Inc Supernus Pharmaceuticals, Inc. Transaction History